JANSSEN
TREMFYA
The Janssen Pharmaceutical has presented the new long-term plaque psoriasis data of Tremfya (guselkumab) at week 100 and week 204.
VOYGAE2 trial:
After four years of treatment, 80% of the patients who were treated with guselkumab 100 mg every eight weeks had improvement in Psoriasis Area and Severity Index (PASI 90) score. Investigator’s Global Assessment (IGA) score of clear (0) or minimal disease (1) was achieved in 82% of patients after four years of treatment, and 51% of patients achieved complete clearance of psoriasis (PASI 100).
The trial also included patient-reported outcomes like Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD).
UCB
Bimekizumab
UCB has presented the superiority results of bimekizumab over placebo and Stelara at week 14 in adult patients suffering from moderate to severe plaque psoriasis. Bimekizumab is an IL-17A and Il-17F inhibitor. The company has presented BE VIVID and BE READY Phase 3 studies, comparing the drug with Stelara and placebo.
BE VIVID
In BE VIVID trial, bimekizumab was compared with Stelara (ustekinumab); bimekizumab 320 mg was indicated every four weeks (Q4W). PASI 90 and IGA 0/1 measured at week 16 are primary endpoints, and the company announced that the product had met both the primary endpoints. PASI 90 at week 16: bimekizumab: 85.0%; ustekinumab: 49.7%; placebo: 4.8 %. 64.2% of patients treated with bimekizumab achieved PASI100 at week 52.
BE READY
In BE READY trial, PASI 90 and IGA 0/1 at week 16 were considered as primary endpoints. The drug is administered every four weeks, 90% of the patients who were on bimekizumab achieved PASI 90 or IGA 0/1, and 68.2% of patients achieved complete skin clearance (PASI 100).
For pipeline, market overview, SLRs, and market access reports (syndicate and customized) please write to sales@firstviewinsight.com